Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to two newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to two newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards are non-qualified stock options for an aggregate of 57,500 shares, 10-year term, exercise price $25.66 per share.

Options vest 25% after one year then monthly over 36 months and are governed by the 2022 Inducement Plan and individual option agreements.

Argus May 1 session

-1.17% close to close 1.0x rel. volume Open Argus

Details

News Market Reaction – DMRA

On May 1, the day this news came out, DMRA closed 1.17% below the previous close.

Data tracked by StockTitan Argus for the May 1 session.

Key Figures

Inducement options: 57,500 shares Exercise price: $25.66 per share Option term: 10 years +5 more

Inducement options

57,500 shares

Aggregate non-qualified stock options granted to two new hires

Exercise price

$25.66 per share

Strike price for new inducement stock options

Option term

10 years

Duration of newly granted inducement stock options

Cash balance

$535 million

Cash as of February 28, 2026 from full-year 2025 results

Net loss 2025

$209.8M

Full-year 2025 net loss driven by acquired in-process R&D charge

R&D expense 2025

$26.9M

Full-year 2025 research and development spending

G&A expense 2025

$9.7M

Full-year 2025 general and administrative expenses

Short interest

2.01% of float

Reported short interest level in risk context

Historical Context

3 past events · Latest: Mar 30

3 events

1. Mar 30

   Inducement equity grants

   24h Move

   -4.8%

   New-hire and CEO-related inducement equity awards under 2022 Inducement Plan.

2. Mar 23

   Management changes

   24h Move

   +27.1%

   Appointment of new CEO and two industry veterans to the board.

3. Mar 19

   Full-year 2025 results

   24h Move

   -5.5%

   Reported 2025 financials, cash position, and development timelines for DMR-001.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, stock option agreement

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"The inducement grants were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"The inducement grants consist of non-qualified stock options to purchase an aggregate of 57,500 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

stock option agreement financial

"subject to the terms and conditions of ... and the terms and conditions of a stock option agreement."

A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to two newly-hired, non-executive employees. The inducement grants were approved by Damora’s independent Compensation Committee and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 57,500 shares of the Damora’s common stock with a 10-year term and an exercise price of $25.66 per share. The options vest as to 25% on the first anniversary of the applicable grant date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a stock option agreement.

About Damora Therapeutics

Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.

Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Damora Therapeutics (DMRA) announce on May 1, 2026 about inducement grants?

Damora granted non-qualified stock options totaling 57,500 shares to two newly hired non-executive employees. According to Damora, the options have a 10-year term, a $25.66 exercise price, and vest 25% after one year then monthly over 36 months.

How do the DMRA inducement option vesting terms work for the new hires?

The options vest 25% on the first anniversary of the grant date, then vest in equal monthly installments over the following 36 months. According to Damora, this schedule applies to the aggregate 57,500-share award under the inducement plan.

What is the exercise price and term for Damora Therapeutics' (DMRA) inducement options?

The exercise price is $25.66 per share and each option has a 10-year term from grant. According to Damora, the awards are non-qualified stock options issued under the 2022 Inducement Plan and subject to option agreements.

Are Damora's (DMRA) inducement grants approved by an independent committee?

Yes. According to Damora, the independent Compensation Committee approved the inducement grants as material inducements under Nasdaq Listing Rule 5635(c)(4). The grants were made to secure the hires and are governed by the company's inducement plan and option agreements.

Will Damora Therapeutics (DMRA) disclose further details about these inducement grants?

Damora indicated the grants are subject to the 2022 Inducement Plan and stock option agreements, implying standard disclosure for equity awards. According to Damora, further specifics would follow in filings or company disclosures as required under Nasdaq rules.